Advanced Czech Biotech: Great past Sad present Promising future Peter Šebo Institute of...

Advanced Czech Advanced Czech BBiotech: iotech:

Great pastGreat pastSad presentSad present

Promising futurePromising future

Peter ŠeboPeter ŠeboInstitute of Biotechnology

Academy of Sciences of the Czech Republic

Prague

Great past:Great past:Used to be extremely strong in tradional biotechnology:Used to be extremely strong in tradional biotechnology:

Crop and animal breedingfermentation industryfermentation industry

• Famous Brewery tradition• Wine, ethanol, baker`s yeats production• Fodder yeast (Biocel Paskov)

Biotransformations:• Aminoacid production, cyclosporin A, ergot alcaloids• Vitamines, food additives etc.

Among pioneers of antibiotics production (penicilin)Among pioneers of antibiotics production (penicilin)

World famous school of continous culture technology World famous school of continous culture technology (at Institute of Microbiology of the Academy of Sciences)

2

Sad present:Sad present:• Lagging behind in cuttingLagging behind in cutting--edgeedge biological research biological research

• LLimited imited and noncompetitive and noncompetitive advanced biotech researchadvanced biotech research

• Almost inextisting advanced biotech intellectual propertyAlmost inextisting advanced biotech intellectual property

• Absence and poor interest of venture capital Absence and poor interest of venture capital

• Minimal Minimal sizesize of advanced biotech industry of advanced biotech industry

4 real companies: 4 real companies: Lonza, Baxter, Contipro, ExbioLonza, Baxter, Contipro, Exbio

• Extremely limiteExtremely limited R&D in advanced biotechd R&D in advanced biotech

• Low numbers of high-tech biotech SMELow numbers of high-tech biotech SME3

Czech advanced biotech – overall description

• 43 biotech companies*• Most companies located in

Prague and Brno metropolitan areas

• Directly employed**: 1800 -2200 people

• Combined yearly turnover**: 4-5 bil CZK (160-200 mil Euro)

• Average yearly growth rate**: 12-16%

* - traditional biotech and foreign trade representations excluded **- estimation based on a incomplete datasetsource of data: Czech Biotech Report 2008, Ernst&Young presentation at G2B conference 2006, company data in public domain

* - traditional biotech and foreign trade representations excluded **- estimation based on a incomplete datasetsource of data: Czech Biotech Report 2008, Ernst&Young presentation at G2B conference 2006, company data in public domain

No of biotech companies* 43

Directly employed** 1800-2200

Combined yearly turnover**

4-5 bil CZK (160-200 mil Euro)

Average yearly growth rate** 12-16%

Czech advanced biotech – overall description

Biotech companies – geographical distribution

Selected biotech companies - Prague

Ascoprot Biotech SME (5 p.) rec. proteinsSME (5 p.) rec. proteinsBIOPREPARÁTY biological plant protectionbiological plant protectionGeneAge Technologies expression profilingexpression profilingGenomac International sequencing/genotypingsequencing/genotypingLentiKat waste water trwaste water treatmenteatment R R&D&D Top-Bio molecular biolmolecular biol.. kits producer SME ( kits producer SME (<5)<5)

Ascoprot Biotech SME (5 p.) rec. proteinsSME (5 p.) rec. proteinsBIOPREPARÁTY biological plant protectionbiological plant protectionGeneAge Technologies expression profilingexpression profilingGenomac International sequencing/genotypingsequencing/genotypingLentiKat waste water trwaste water treatmenteatment R R&D&D Top-Bio molecular biolmolecular biol.. kits producer SME ( kits producer SME (<5)<5)

Sel. biotech companies – Central Bohemia

AppGenics SME , transgenic rabbits, hEPO SME , transgenic rabbits, hEPO recombinant recombinant

proteinsproteinsApronex SME, recombinant proteinsSME, recombinant proteins (4 p)(4 p) Baxter Czech flu vaccine production siteflu vaccine production site Biologicals SME, forensics, HCV-Y-ScreenSME, forensics, HCV-Y-ScreenEXBIO SME, Mab and reagent producer SME, Mab and reagent producer Lonza Biotec fermentation fermentation plant and R&D plant and R&D

FDA-registered pharma enzymesFDA-registered pharma enzymesProteix SME, recombinant proteins (3 p)SME, recombinant proteins (3 p)rEcoli SME,SME, recombinant proteinsrecombinant proteinsVIDIA SME, clinical diagnostic kitsSME, clinical diagnostic kits

AppGenics SME , transgenic rabbits, hEPO SME , transgenic rabbits, hEPO recombinant recombinant

proteinsproteinsApronex SME, recombinant proteinsSME, recombinant proteins (4 p)(4 p) Baxter Czech flu vaccine production siteflu vaccine production site Biologicals SME, forensics, HCV-Y-ScreenSME, forensics, HCV-Y-ScreenEXBIO SME, Mab and reagent producer SME, Mab and reagent producer Lonza Biotec fermentation fermentation plant and R&D plant and R&D

FDA-registered pharma enzymesFDA-registered pharma enzymesProteix SME, recombinant proteins (3 p)SME, recombinant proteins (3 p)rEcoli SME,SME, recombinant proteinsrecombinant proteinsVIDIA SME, clinical diagnostic kitsSME, clinical diagnostic kits

Sel. biotech companies – South Moravia

BioVendor SME, recombinant proteins, diagnosticsSME, recombinant proteins, diagnosticsBioveta veterinary vaccines Rveterinary vaccines R&D and production&D and productionEnantis SME, recombinant dehalogenasesSME, recombinant dehalogenases

contract research in protein engineering contract research in protein engineering EPS SME, bioremediation, biogas Moravian-Biotechnology SME, custom antibody servicesSME, custom antibody servicesTEST-LINE SME, human and veterinary diagnosticsSME, human and veterinary diagnostics

BioVendor SME, recombinant proteins, diagnosticsSME, recombinant proteins, diagnosticsBioveta veterinary vaccines Rveterinary vaccines R&D and production&D and productionEnantis SME, recombinant dehalogenasesSME, recombinant dehalogenases

contract research in protein engineering contract research in protein engineering EPS SME, bioremediation, biogas Moravian-Biotechnology SME, custom antibody servicesSME, custom antibody servicesTEST-LINE SME, human and veterinary diagnosticsSME, human and veterinary diagnostics

Sel. biotech companies – remaining regions GENERI BIOTECH SME, oligonucleotides, SME, oligonucleotides,

DNA DNA genotyping servicesgenotyping servicesContipro Group world leader in hyaluronic acidGMP recombinant defensins, wound healing GMP recombinant defensins, wound healing R&D R&D

GENERI BIOTECH SME, oligonucleotides, SME, oligonucleotides, DNA DNA

genotyping servicesgenotyping servicesContipro Group world leader in hyaluronic acidGMP recombinant defensins, wound healing GMP recombinant defensins, wound healing R&D R&D

AgroBio agrochemicals and agrobiologicalsBiocel pulp industry – fodder yeast pulp industry – fodder yeast producerproducer IVAX Pharmaceuticals , generics, ergot alcaloidsOlChemIm SME, phytohormones, antibodies (5 SME, phytohormones, antibodies (5 p)p)

AgroBio agrochemicals and agrobiologicalsBiocel pulp industry – fodder yeast pulp industry – fodder yeast producerproducer IVAX Pharmaceuticals , generics, ergot alcaloidsOlChemIm SME, phytohormones, antibodies (5 SME, phytohormones, antibodies (5 p)p)

B.P.Medical SME,SME, bioactivity testingbioactivity testing ENVISAN-GEM bioremediation GEN-TREND SME, diagnostics and SME, diagnostics and proteinsproteins

B.P.Medical SME,SME, bioactivity testingbioactivity testing ENVISAN-GEM bioremediation GEN-TREND SME, diagnostics and SME, diagnostics and proteinsproteins

Promising futurePromising future::• Government recognizes the problem Government recognizes the problem

Advanced biotechnology and molecular biology among strategic longterm Advanced biotechnology and molecular biology among strategic longterm research orientations research orientations - funding schemes- funding schemes

More funds than competent individuals and teams available…More funds than competent individuals and teams available…

•Good culture, education, enough PhDs, qualified manpowerGood culture, education, enough PhDs, qualified manpower

•National applied research support schemes (NPV )National applied research support schemes (NPV )

• Incentives for Academia collaborations with IndustryIncentives for Academia collaborations with Industry

• ERDF funds for OP R&D for Innovation and Enterprise for Innovation / pert of ERDF funds for OP R&D for Innovation and Enterprise for Innovation / pert of going to biotechgoing to biotech

• Institute of Biotechnology AS CR, v.v.i. founded on January 1, 2008Institute of Biotechnology AS CR, v.v.i. founded on January 1, 2008

• BIOCEV, CEITEC and several other major projects in preparationBIOCEV, CEITEC and several other major projects in preparation

11

Biotech research - geographical distribution

University students vs. life science students:geographical distribution

CentersCenters of b of biotech iotech research research at Universities at Universities • Centre of Integrated Genomics: AS CR, Charles University

Institute of Chemical Technology – genomes, gene expression

• Genomics of animals: Veterinary and Pharmaceutical University Brno, South Bohemian - genomics of farm animals

• Centre of Proteomics : Military Academy in Hradec Králové

• Centre for Biocatalysis and Biotransformation: AS CR, Masaryk University, South Bohemian University – enzyme engineering

• Centre for Molecular and Gene Biotechnology: AS CR, ICT, 5 companies – biosynthesis, biotranformation proteins

• Centre for Research of Structure and Mechanism of Action of Potential Drugs: School of Pharmacy, Hradec Králové + companies – gene therapies, biologically active substances

• Medicinal and pharmaceutical chemistry: Palacky University Olomouc – biologically active plant substances

CentersCenters of b of biotech iotech research research at Universities at Universities

Since 2005 – major investments at Masaryk University

ILBIT

Academy of Sciences

17

• Leading basic research institution of CR

• Funded from state budget mainly

• ~6400 employees, >50% university graduates and PhDs

• Not a University – Network of 60 institutes

All transformed to Public Research Institutes by January 1, 2007

http://www.cas.cz/en

Basic Facts and Mission of the ASCR

http://www.cas.cz/en

Flemingovo nám. 2Prague 6, CZ-16637Czech Republic

Phone: +420 220 183 111Fax: +420 224 310 955E-mail: [email protected]

http://www.img.cas.cz

New Institute's building to completed in 2007

mailto:[email protected]

INSTITUTE OF MOLECULAR GENETICS AS CR

Molecular & Cell Biology

Molecular & Applied Immunology

Developmental Biology

Virology

Molecular Genetics

Recombinant proteins

Monoclonal antibodies

Cellular vaccines

Monoclonal antibodies

Unique mouse strains

Unique chicken inbreds

Inhibition of HIV Protease by Bizarre CompoundsInhibition of HIV Protease by Bizarre Compounds

„WIDE-OPEN“ PROTEASE IN THE COMPLEX

HIV PR dimer + 2 carborane molecules + tetrapeptide

Co

= BH

= CH

Carboranes: Boron-containing polyhedral compounds

previously used in boron neutron capture therapy

Ki = 66 nM

X-ray structure

Cigler Cigler et al.et al. (2005) PNAS 102, 15394-9 (2005) PNAS 102, 15394-9

Dr. Ladislav Andera

http://www.img.cas.cz/[email protected]

Cell signalling and apoptosis Cell signalling and apoptosis

TRAIL induces death of tumor cells

TRAIL is produced as soluble trimer

TRAIL-based drugs in combination with other cancer therapies

Apoptosis-inducing humanized monoclonal antibodies against TRAIL receptors DR4 and DR5

Institute of Experimental MedicineInstitute of Experimental Medicine (IEM) (IEM)

Prof.Prof. Eva Sykova, DEva Sykova, D..Sc.Sc.

phone:phone: +420 296 442 230+420 296 442 230fax:fax: +420 296 442 782+420 296 442 [email protected]@biomed.cas.czhttp://uemweb.biomed.cas.cz http://uemweb.biomed.cas.cz

Stem cell research at IEM

iron nanoparticles for in vivo iron nanoparticles for in vivo NNMR imagingMR imaging of stem cells of stem cells

Biodegradable hBiodegradable hydrogelydrogelss for stem cell ingrowth into hydrogel for stem cell ingrowth into hydrogel

implants implants

in spinal cord lesion reparationin spinal cord lesion reparation

Growth of olfactory glial ensheathing cellsGrowth of olfactory glial ensheathing cells

Establishing and characterizing human embryonic stem cells Establishing and characterizing human embryonic stem cells

(Dr. P. Dvorak – among the world(Dr. P. Dvorak – among the world`s `s leaders)leaders)

[email protected]@biomed.cas.czhttp://uemweb.biomed.cas.czhttp://uemweb.biomed.cas.cz

Invasion of axons into the hydrogel implantedinto the spinal cord injury

Institute of Experimental Medicine ASCR

E. Sykova [email protected]

Institute of Physiology & Centre of Cardiovascular Research

Videnska 1083, 142 20 Prague 4-Krc, Czech Republic

Phone: +420 2 9644 1111Fax: +420 2 4106 2488

E-mail: [email protected]

- Bioartificial vascular tissue prostheses

- Regionally-selective cell adhesion on micropatterned surface

- Bone tissue engineering on nanostructured materials

http://www2.biomed.cas.cz/fgu/centrum/images/znak.eps

Innovation of clinically used vascular prosthesesInnovation of clinically used vascular prostheses: : coating with extracellular matrix (ECM) molecules and endothelializationcoating with extracellular matrix (ECM) molecules and endothelialization

Endothelial cells grow and differentiate

On the inner surface, laminin or fibrin were immobilized

Inner surface

[email protected]

Bone tissue engineering Human osteoblast-like MG 63 cells

in “three-dimensional“ porous scaffolds

Cells in depth ofCells in depth of::0 – 60 0 – 60 m (blue signal)m (blue signal) 80 80 – – 160 160 m (green) m (green) 180 – 220 180 – 220 m (yellow)m (yellow) 240 – 300 240 – 300 m (orange)m (orange)320 – 400 320 – 400 m (red)m (red) 420 – 480 420 – 480 m (violet)m (violet)

400 m______

Scaffolds made of lactide and glycolide a copolymer

Average pore size and depth ~400 µm

Institute of Microbiology Institute of Microbiology

VidenskaVidenska 1083 1083CZ-142 20 Prague 4CZ-142 20 Prague 4Czech RepublicCzech Republic

phone: +420 296 442 341phone: +420 296 442 341fax: +420 296 442 201fax: +420 296 442 201e-mail:e-mail: mbu mbu@[email protected]

http://www.biomed.cas.cz/mbu/en/http://www.biomed.cas.cz/mbu/en/

http://www.biomed.cas.cz/mbu/en/

• Pioneered continous culture research in 60Pioneered continous culture research in 60`s…`s…

• microalgae cultivation biotechnologymicroalgae cultivation biotechnology

• Biotechnological pilot plantBiotechnological pilot plant

• Targeted polymeric drugsTargeted polymeric drugs

• Biotransformation of glycansBiotransformation of glycans

• Antigen delivery tools for immunotherapy and Antigen delivery tools for immunotherapy and diagnosticsdiagnostics

Institute of Microbiology Institute of Microbiology

http://www.biomed.cas.cz/mbu/en/http://www.biomed.cas.cz/mbu/en/

Laboratory of Laboratory of Algae Algae BiotechnologyBiotechnology

• Isotopically labelled chemicals (13C, 15N, 2H)

• Bioactive compounds for pharmaceuticals, cosmetics and nutrition

• Solar bioreactors

http://www.alga.cz/en/http://www.alga.cz/en/

[email protected]@alga.cz

Pilot plant for microalgal biomass

www.greentech.cz

Plasma membrane

Extracellularmatrix

Endosome

Intracellularfluid

Lysosome

Targeted cancerostatic drug actionTargeted cancerostatic drug action

rihovarihova@@biomed.cas.czbiomed.cas.cz

• Targeted therapy = Reduced side effects

• Stimulation of anti-cancer immunity

• Improved efficiency

• Much better survival of treated animals

http://www.biomed.cas.cz/mbu/en/

Antigen delivery tools inducing cellular immune response Antigen delivery tools inducing cellular immune response in vaccination, immunotherapy and diagnosticsin vaccination, immunotherapy and diagnostics

Proteasome

Endosome

MHC II peptide

CD4+ T cell

Transporter associated with antigen procesing

MHC I

MHC II

Golgi

Endoplasmatic reticulum

MHC I peptide

AC

AC AC

ACAC

Ca+

AC

RepeatsAC

Translocationinto cytosol

Insertedantigen

CD8+ T cell

Repeats

?

?

M2 integrin receptorCD11b/CD18

Ag

Ag

AgAg Ag

Ag

Antigen-specific T cells:Antigen-specific T cells:

P. Sebo P. Sebo http://l125lsx.mbu.cas.cz/Lab125/http://l125lsx.mbu.cas.cz/Lab125/ sebosebo@@biomed.cas.czbiomed.cas.cz

Current status of antigen ACT delivery technologyCurrent status of antigen ACT delivery technologyIImmunity against virusmmunity against viruseses

Immunotherapy of transplanted tumors Immunotherapy of transplanted tumors

Protective immunity against Protective immunity against Plasmodium Plasmodium (mouse malaria model)(mouse malaria model)

Immunotherapy of Immunotherapy of experimental experimental tumorstumors (HPV16 – induced) (HPV16 – induced)

ImprovementImprovement of latent tuberculosis of latent tuberculosis diagnosing diagnosing

• PPhase I&II hase I&II clinical trial in preparation for:clinical trial in preparation for:

– melanoma melanoma treatementtreatement

– HPV16-induced cervical carcinomaHPV16-induced cervical carcinoma

((US PatentUS Patent No. 5,503,829 No. 5,503,829,, No No. . 5,679,7845,679,784,, No. 5,935,580 No. 5,935,580, , EU Patent applicationEU Patent application No. No. 03291486.303291486.3, , USUS Prov 03495, 6094 (2003)Prov 03495, 6094 (2003) ) )

http://l125lsx.mbu.cas.cz/Lab125/http://l125lsx.mbu.cas.cz/Lab125/ sebosebo@@biomed.cas.czbiomed.cas.cz

INSTITUTE OF EXPERIMENTAL BOTANY

• Cytokinins as cell-division-inhibiting substances for cancer

treatment

• Sorted chromosomes for plant genomics

• Edible vaccines in plants

Phone: +420 220 390 453 Fax: +420 220 390 456 E-mail: [email protected]

www.ueb.cas.cz

Institute of Experimental Botany Institute of Experimental Botany Rozvojová 135 Rozvojová 135 165 00 Prague 6 - Lysolaje 165 00 Prague 6 - Lysolaje Czech Republic Czech Republic

mailto:[email protected]

Senescent human fibroblasts treated (A) and untreated (B) with a cytokinin. Blue-green color is indicates ageing marker

Cytokinins Prevent Aging of Human and Plant Cells:Cytokinins Prevent Aging of Human and Plant Cells:

Synthesis and use of cytokinins and their synthetic analogs M. Strnad et.al. http://rustreg.upol.cz/

IInhibitornhibitorss of cyclin-dependent kinases (CDK) of cyclin-dependent kinases (CDK) R-Roscovitine - R-Roscovitine - ((SSeliciclib)eliciclib)R R – phase II of clinical trials for cancer– phase II of clinical trials for cancer

C D K 2 / roscov itine co-c rys ta l

-Multiple myeloma

-B-cell Chronic Lymphocytic Leukemia

- Mantle Cell Lymphoma.

Phase II clinical trial for Non-Small Cell Lung Cancer treatment

M. Strnad et.al. http://rustreg.upol.cz/

Institute of Biotechnology Institute of Biotechnology

Founded by Academy of Sciences Founded by Academy of Sciences January 1, 2008January 1, 2008

37

38

IBTIBT seeding groups 2007-2010 seeding groups 2007-2010

• 2008: IBT/Sebo2008: IBT/SeboP. BartůněkP. Bartůněk - Chemical genetics- Chemical geneticsM. KubistaM. Kubista - Single cell expression profiling- Single cell expression profilingJ. NeužilJ. Neužil - Molecular and recombinant therapeutics- Molecular and recombinant therapeuticsJ. PěknicováJ. Pěknicová - Diagnostics for reproductive medicine- Diagnostics for reproductive medicineR. SedláčekR. Sedláček - Transgenic Animals- Transgenic AnimalsŠ. Růžičková Š. Růžičková - Diagnostics of autoimmune diseases - Diagnostics of autoimmune diseasesP. ŠeboP. Šebo - Recombinant binding proteins (ligands)- Recombinant binding proteins (ligands)

• 2009:2009:• G. PavlinkovaG. Pavlinkova - gene expression regulation in diabetic - gene expression regulation in diabetic

embryopathyembryopathy• New recruitmentsNew recruitments

• 20010 / 2011 Evaluation/new recruitements• 2012 Recruitement of new groupleaders

39

S78E or S78A or S78G

A186F or A186Y or A186W

I166E or I166Q or I166N or I166D

Setting-up the ribosome display technology on the Setting-up the ribosome display technology on the model of Improvement of IFNmodel of Improvement of IFN receptor binding site receptor binding site

Calculations and rational design: J. Vondrášek

Vestec at Prague

Regional development and competitiveness Regional development and competitiveness tthrough hrough promotion ofpromotion of cutting-edge biotechnology and cutting-edge biotechnology and

biomedical R&D in Czech Republicbiomedical R&D in Czech Republic

European Regional Development FundEuropean Regional Development FundOperational Program R&D for InnovationOperational Program R&D for Innovation

2007 - 20132007 - 2013

Biotech Biotech && Biomed Research CenterBiomed Research Center of Academy of Sciences and Charles Universityof Academy of Sciences and Charles University

http://www.natur.cuni.cz/

Biotech&Biomed Res. Center of Academy of Sciences and Charles University

20 000 m20 000 m2 2 of Rof R&&D facilitiesD facilities

450 researchers450 researchers

150 students and postdocs150 students and postdocs

~~100100 M M€€

2012 – the true START!2012 – the true START!


Center of Molecular BiotechnologiesCenter of Molecular Biotechnologies

Emphasis on:Emphasis on: protein research and protein research and

engineering engineering - - Structural BiologyStructural Biology

Openings for discovering new Openings for discovering new interesting molecules for therapy interesting molecules for therapy and diagnosticsand diagnostics

Processes for producing Processes for producing recombinant therapeutic and recombinant therapeutic and diagnostic proteins diagnostic proteins of extremely of extremely high added valuehigh added value

qRT/PCR for clinical and qRT/PCR for clinical and research applications research applications

Licensing to biotech companiesLicensing to biotech companies

Start-up and spin-off biotechsStart-up and spin-off biotechs

Transgenic cells, animals Transgenic cells, animals and plants and plants

Genetic manipulation of producing cells Genetic manipulation of producing cells

Culture techniques for bacteria and yeastsCulture techniques for bacteria and yeasts

AAdvanced cell culture techniquesdvanced cell culture techniques

Advanced biomacromolecule (protein) Advanced biomacromolecule (protein) separation and purificationseparation and purification

Cutting-edge biomacromolecule analysis and Cutting-edge biomacromolecule analysis and characterization methodscharacterization methods

SStructural biology and protein engineeringtructural biology and protein engineering

BBioinformatics and modelingioinformatics and modeling

Nanobiotechnologies – molecular motorsNanobiotechnologies – molecular motors

BiosensorsBiosensors


•Tissue engineering and therapies•Cellular therapies using stem cells •Immunobiology of stem cells•Application of stem cells in:

• neurology, cardiology, diabetology and hepatology•ophthalmology, stomatology a otolaryngology

•Stem cell use on scaffolds for bone and cartilage reconstruction•Biomaterials•Nanotechnologies for cell and tissue imaging•Nanotechnologies for therapy and diagnostics

Center of Regenerative Medicine

[email protected]

Academy of SciencesPublic research institutes:

Charles University

BBinstitute of Biotechnologyinstitute of Biotechnology ((foundedfounded 1.1.2008) 1.1.2008)

Institute of PhysiologyInstitute of Physiology

Institute of MicrobiologyInstitute of Microbiology

Institute of Experimental MedicineInstitute of Experimental Medicine

Institute of macromolecular ChemistryInstitute of macromolecular Chemistry

Institute of Molecular GeneticsInstitute of Molecular Genetics

Faculty of ScienceFaculty of Science

11stst Medical School Medical School


http://www.biomed.cas.cz/fgu/en/index.php

http://www.biomed.cas.cz/mbu/cz/

http://uemweb.biomed.cas.cz/

http://www.img.cas.cz/main.php?lang=en&subject=1

http://www.natur.cuni.cz/

Pros and cons for the future

Strong points Weak points

long tradition in classic biotechnology

lag in cutting-edge molecular biotechnology

established education system; well qualified and cheap manpower

insufficient interaction of academia with industry; brain-drain

improved infrastructure in R&D; restructuring research organizations

missing tradition of spin-offs; lack of managers trained in science

growing awareness on intellectual property protection in academia

lack of funding for patenting in academia; lack of venture capital

increasing funding to R&D; long-term funding

growing bureaucracy; complex rules for the use of funding

Summary of pros and cons for the future


long tradition in classic biotechnology Lagging behind in cutting-edge molecular biotechnologies

established education system; well qualified and cheap manpower

insufficient interaction of academia with industry; brain-drain








long tradition in classic biotechnology Lagging behind in cutting-edge molecular biotechnologies

established education system; well qualified and affordable manpower

insufficient interaction of academia with industry; past brain-drain







Summary of pros and cons for the future

Special Thanks:Special Thanks:

Jiří DamborskýJiří Damborský

Michal KostkaMichal Kostka

Contact:Contact:

[email protected]@biomed.cas.cz

Peter Sebo, PhD.Peter Sebo, PhD.

BIOCEV coordinatorBIOCEV coordinator

Institute of Biotechnology AS CR, v.v.i.Institute of Biotechnology AS CR, v.v.i.

Academy of Sciences of the Czech RepublicAcademy of Sciences of the Czech RepublicVidenska 1083Videnska 1083

142 20 Prague 4142 20 Prague 4Czech RepublicCzech Republic

GSM: (+420) 774 798 121GSM: (+420) 774 798 121office: (+420) 241 062 762office: (+420) 241 062 762

http://www.http://www.ibtibt.cas.cz.cas.cz

http://125lsx.mbu.cas.cz/Lab125/http://125lsx.mbu.cas.cz/Lab125/

Advanced Czech Biotech: Great past Sad present Promising future Peter Šebo Institute of...

Documents

Transcript of Advanced Czech Biotech: Great past Sad present Promising future Peter Šebo Institute of...